Vicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $5.10, for a total transaction of $112,200.00. Following the transaction, the director owned 1,298,391 shares in the company, valued at $6,621,794.10. This represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Vir Biotechnology Stock Performance

Shares of VIR opened at $5.49 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $14.45. The firm’s 50-day simple moving average is $5.22 and its two-hundred day simple moving average is $7.09. The stock has a market cap of $758.94 million, a PE ratio of -1.30 and a beta of 1.22.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05). Vir Biotechnology had a negative return on equity of 47.46% and a negative net margin of 2,769.04%. The company had revenue of $3.03 million during the quarter, compared to the consensus estimate of $8.59 million. During the same period in the prior year, the firm earned ($0.48) earnings per share. The business’s revenue for the quarter was down 94.6% compared to the same quarter last year. Equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

VIR has been the topic of several research reports. The Goldman Sachs Group cut their price objective on Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, April 17th. Needham & Company LLC restated a “buy” rating and set a $14.00 price target on shares of Vir Biotechnology in a research report on Thursday, May 22nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.86.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vir Biotechnology in the fourth quarter worth approximately $42,000. GAMMA Investing LLC raised its holdings in Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after acquiring an additional 5,972 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Vir Biotechnology in the 4th quarter valued at approximately $60,000. PNC Financial Services Group Inc. lifted its position in Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,999 shares in the last quarter. Finally, FORA Capital LLC purchased a new stake in Vir Biotechnology during the 1st quarter valued at $70,000. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).